[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:adult-t-lymphoblastic-lymphoma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":35,"states":36},"Adult T Lymphoblastic Lymphoma",4,3,[8,16,22,28],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07513129","Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma",[12],"Phase 1","RECRUITING","2026-08-26T02:18:06.247899Z","2026-05-05T02:43:27.944236Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT07220993","Novel Unedited Allo Cell Therapy For High Risk T-Cell Malignancies Using CD7-Specific Car T Cells",[12],"2026-08-26T02:15:36.077529Z","2026-05-05T02:43:28.987867Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":26,"content_modified":27},"NCT03081910","Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen",[12],"2026-08-26T02:18:57.189473Z","2026-05-05T02:43:26.923493Z",{"nct_id":29,"title":30,"phases":31,"status":32,"updated_at":33,"content_modified":34},"NCT03690011","Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells",[12],"ACTIVE_NOT_RECRUITING","2026-08-03T03:05:09.265674Z","2026-05-05T02:43:27.128098Z",[],[37],{"state":38,"count":5,"slug":39},"Texas","texas"]